Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See [Seeking Alpha]
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: Seeking Alpha
NDV-01 demonstrated a 76% 12-month complete response rate and favorable safety, supporting advancement into Phase 3 with two registrational pathways. RLMD secured ~$160m in new funding, extending its cash runway into 2029, but faces entrenched competition from JNJ's Inlexzo and UroGen's Zusduri. Issuing a Hold rating: while RLMD's assets are derisked by positive data, competitive and execution risks temper conviction in best-in-class potential. Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios. Learn More » Kathrin Ziegler/DigitalVision via Getty Images Investment Overview Earlier this month, Relmada Therapeutics, Inc. ( RLMD ) stock surged in value from ~$4.5 to $7, up ~55%. The gains were triggered by the Coral Gables, Florida-based biotech's reporting Phase 2 clinical study data for its drug delivery More on my IG service If you are interested in keeping up to date with stocks maki
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director [Yahoo! Finance]Yahoo! Finance
- Here's What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics (RLMD) is now covered by Piper Sandler. They set an "overweight" rating and a $12.00 price target on the stock.MarketBeat
- Relmada Therapeutics (RLMD) had its price target raised by Mizuho from $10.00 to $19.00. They now have an "outperform" rating on the stock.MarketBeat
- Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ... [Yahoo! Finance]Yahoo! Finance
RLMD
Earnings
- 3/19/26 - Miss
RLMD
Sec Filings
- 3/20/26 - Form 8-K
- 3/19/26 - Form 10-K
- 3/9/26 - Form 8-K
- RLMD's page on the SEC website